Actively Recruiting
Comparing IV Ketamine and Esketamine Spravato for Treatment-Resistant Depression The OBSERVE Study
Led by Yale University · Updated on 2026-09-03
450
Participants Needed
8
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
This observational study follows patients with treatment-resistant depression who are starting or continuing treatment with either intravenous IV ketamine or intranasal esketamine Spravato. It aims to compare these two approaches by collecting information on patient satisfaction, usage patterns, long-term effectiveness, and safety over a five-year period. The study will enroll 450 patients across six sites, including academic medical centers and community psychiatric practices. Participants receive either IV ketamine or Spravato as prescribed by their clinicians for moderate to severe treatment-resistant depression without psychotic features. Patients newly starting treatment or continuing treatment within 75 days are eligible. The study observes these treatments in routine clinical use without assigning specific interventions. During the study, participants provide data and assessments at regular intervals up to six months, including treatment satisfaction using the TSQM-9 questionnaire, depression severity reported by patients and clinicians, treatment patterns such as number of sessions and dosage, reasons for stopping treatment, and monitoring of adverse events. The study continues to observe participants for up to five years to gather long-term follow-up information on safety and effectiveness.
CONDITIONS
Brief Title
The OBSERVE Protocol
Research Team
C
Cindy Voghell
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here